211 related articles for article (PubMed ID: 21526503)
1. Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Hus I; Tabarkiewicz J; Lewandowska M; Wasiak M; Wdowiak P; Kusz M; Legieć M; Dmoszyńska A; Roliński J
Folia Histochem Cytobiol; 2011; 49(1):153-60. PubMed ID: 21526503
[TBL] [Abstract][Full Text] [Related]
2. DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.
Flörcken A; Kopp J; Kölsch U; Meisel C; Dörken B; Pezzutto A; Westermann J
Hum Vaccin Immunother; 2016 May; 12(5):1117-23. PubMed ID: 26864050
[TBL] [Abstract][Full Text] [Related]
3. [Expression of CC-chemokine ligand 18 (CCL18) in the serum and pleural effusion of non-small-cell lung cancer patients and its regulatory effect on the differentiation of monocyte-derived dendritic cells].
Chen L; Zhou Q; Zhong F; Wang Q; Fang Y; Yang K; Guan S
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):823-7. PubMed ID: 25620478
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia.
Eisendle K; Lang A; Eibl B; Nachbaur D; Glassl H; Fiegl M; Thaler J; Gastl G
Br J Haematol; 2003 Jan; 120(1):63-73. PubMed ID: 12492578
[TBL] [Abstract][Full Text] [Related]
5. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha.
Wang C; Al-Omar HM; Radvanyi L; Banerjee A; Bouman D; Squire J; Messner HA
Exp Hematol; 1999 Jul; 27(7):1176-84. PubMed ID: 10390193
[TBL] [Abstract][Full Text] [Related]
6. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
8. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Schütz C; Inselmann S; Saussele S; Dietz CT; Mu Ller MC; Eigendorff E; Brendel CA; Metzelder SK; Bru Mmendorf TH; Waller C; Dengler J; Goebeler ME; Herbst R; Freunek G; Hanzel S; Illmer T; Wang Y; Lange T; Finkernagel F; Hehlmann R; Huber M; Neubauer A; Hochhaus A; Guilhot J; Xavier Mahon F; Pfirrmann M; Burchert A
Leukemia; 2017 Apr; 31(4):829-836. PubMed ID: 28074067
[TBL] [Abstract][Full Text] [Related]
9. The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia.
Zhao ZG; Xu W; Sun L; Li WM; Li QB; Zou P
Eur J Cancer; 2012 Aug; 48(12):1884-95. PubMed ID: 22129888
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
[TBL] [Abstract][Full Text] [Related]
11. Assessment of regulatory T cells (Tregs) and Foxp3 methylation level in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy.
Sabir SF; Matti BF; Alwatar WMA
Immunogenetics; 2023 Apr; 75(2):145-153. PubMed ID: 36567345
[TBL] [Abstract][Full Text] [Related]
12. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
[TBL] [Abstract][Full Text] [Related]
13. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
14. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
16. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.
Dietz AB; Bulur PA; Erickson MR; Wettstein PJ; Litzow MR; Wyatt WA; Dewald GW; Tefferi A; Pankratz VS; Vuk-Pavlović S
J Hematother Stem Cell Res; 2000 Feb; 9(1):95-101. PubMed ID: 10738977
[TBL] [Abstract][Full Text] [Related]
17. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells.
Engels FH; Koski GK; Bedrosian I; Xu S; Luger S; Nowell PC; Cohen PA; Czerniecki BJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10332-7. PubMed ID: 10468608
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response.
Eibl B; Ebner S; Duba C; Böck G; Romani N; Erdel M; Gächter A; Niederwieser D; Schuler G
Genes Chromosomes Cancer; 1997 Nov; 20(3):215-23. PubMed ID: 9365828
[TBL] [Abstract][Full Text] [Related]
19. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
[TBL] [Abstract][Full Text] [Related]
20. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Jiang Q; Yu L; Gale RP
J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]